Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen-Reference-Cited by-同舟云学术

Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen

Published:2021-05-10 Issue:9 Volume:35 Page:1423-1432
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Keene Claire M.,Griesel Rulan,Zhao Ying,Gcwabe Zimasa,Sayed Kaneez,Hill Andrew,Cassidy Tali,Ngwenya Olina,Jackson Amanda,van Zyl Gert,Schutz Charlotte,Goliath Rene,Flowers Tracy,Goemaere Eric,Wiesner Lubbe,Simmons Bryony,Maartens Gary,Meintjes Graeme

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference26 articles.

1. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, noninferiority, phase 3b trial;Aboud;Lancet Infect Dis,2019

2. Global epidemiology of drug resistance after failure of WHO recommended fi rst-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study;Lancet Infect Dis,2016

3. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised noninferiority trial;Wijting;Lancet HIV,2017

4. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV;Gallant;N Engl J Med,2006

5. Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial;Hakim;Lancet Infect Dis,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia;PLOS ONE;2024-09-06

2. Three Year Outcomes after Programmatic Transitioning to Dolutegravir in the Context of Severe Civil Unrest in Haiti;2024-08-14

3. Development and emerging trends of drug resistance mutations in HIV: a bibliometric analysis based on CiteSpace;Frontiers in Microbiology;2024-05-15

4. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen;JAIDS Journal of Acquired Immune Deficiency Syndromes;2024-05-01

5. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review;Viruses;2024-03-04